The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model Matthew O'Brien, Thuy Quach,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

In-vitro interaction of azithromycin and fluoroquinolones against gram-positive and gram-negative bacteria Matthew W. Ruble, Deborah H. Gilbert, Stephen.

Grepafloxacin: microbiological properties

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Herpes zoster in non-hospitalized children

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98 J. Robert, E. Cambau, K. Grenet, D.

Hydatid disease Clinical Microbiology and Infection

Link between intracellular pathogens and cardiovascular diseases

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

P. Davey, C. Pagliari, A. Hayes Clinical Microbiology and Infection

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Alasdair P. MacGowan, Caroline Rynn, Mandy Wootton, Karen E. Bowker, H

Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide F.G. Araujo, T.L. Slifer, J.S. Remington Clinical.

Structure of grepafloxacin relative to activity and safety profile

Evaluation of antibacterial activity of cefodizime, ceftriaxone and cefonicid in Klebsiella pneumoniae-infected guinea pigs Lorenzo Drago, Barbara Mombelli,

Inga Odenholt, Elisabeth Löwdin, Otto Cars

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

Cephalosporins: a pharmacological update

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections P.S. Hicks, B.

M. Roche, H. Humphreys, E. Smyth, J. Phillips, R. Cunney, E

Sepsis and neutropenia induced by clozapine

Uncommon opportunistic fungi: new nosocomial threats

André Bryskier Clinical Microbiology and Infection

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

Isolation rate, T-serotyping and susceptibility to antibiotics of Group A Streptococcus from pediatric infections in Athens* M. Kanellopoulou, A. Makri,

Laboratory diagnosis of Clostridium difficile disease

W.A. Craig Clinical Microbiology and Infection

Recent developments in staphylococcal scalded skin syndrome

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

A. Bryskier Clinical Microbiology and Infection

Pathogenesis of catheter-related infections: lessons for new designs

T.M. File Clinical Microbiology and Infection

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Antibacterial drug discovery in the 21st century

Community-acquired pneumonia: epidemiologic and clinical consideration

Grepafloxacin: pharmacokinetics and tissue penetration

Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women F. Auquer, F. Cordón, E. Gorina, J.C. Caballero,

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Clinical infection services—the Leiden experience

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

Clinical Microbiology and Infection

Clinical Microbiology and Infection

Overview of cefixime use in community-acquired infections

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Carratalà J. Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Gebhard Feierl, Christian Berghold, Theresia Fürpaβ, Egon Marth

Typing of Clostridium difficile

Impact of antibiotic restrictions: the patient's perspective

Decision-making in otitis media in children, Part I: epidemiologic data and definitions for a reliable cost-effectiveness analysis Bernard Grenier Clinical.

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

Abstracts Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model Matthew O'Brien, Thuy Quach, Deborah Gilbert, Michael N. Dudley, Stephen H. Zinner Clinical Microbiology and Infection Volume 5, Issue 1, Pages 12-15 (January 1999) DOI: 10.1111/j.1469-0691.1999.tb00092.x Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Time course of central compartment antibiotic concentrations: (a) ciprofloxacin simulated at 750 mg every 12 h; (b) trovafloxacin simulated at 300 mg (▪) and 200 mg (▴) every 24 h. Clinical Microbiology and Infection 1999 5, 12-15DOI: (10.1111/j.1469-0691.1999.tb00092.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Mean of duplicate bacterial counts for six strains of Streptococcus pneumoniae exposed to simulated trovafloxacin dosing at 300 mg every 24 h in an in vitro dynamic model. Clinical Microbiology and Infection 1999 5, 12-15DOI: (10.1111/j.1469-0691.1999.tb00092.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Mean of duplicate bacterial counts for the same six strains of Streptococcus pneumoniae as in Figure 2 exposed to simulated ciprofloxacin dosing at 750 mg every 12 h in an in vitro dynamic model. Clinical Microbiology and Infection 1999 5, 12-15DOI: (10.1111/j.1469-0691.1999.tb00092.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 Mean of duplicate bacterial counts for three strains of Streptococcus pneumoniae exposed to simulated trovafloxacin dosing at 200 mg every 24 h (a) and to ciprofloxacin dosing at 750 mg every 12 h (b). Clinical Microbiology and Infection 1999 5, 12-15DOI: (10.1111/j.1469-0691.1999.tb00092.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions